2021 Fiscal Year Final Research Report

Development of virotherapy for osteosarcoma pulmonary metastases using stem cells as carriers

Research Project

PDF

Project/Area Number	19K22697
Research Category	Grant-in-Aid for Challenging Research (Exploratory)
Allocation Type	Multi-year Fund
Review Section	Medium-sized Section 56:Surgery related to the biological and sensory functions and related fields
Research Institution	Hyogo Medical University
Principal Investigator	Kubo Shuji 兵庫医科大学, 医学部, 准教授 (10441320)
Co-Investigator(Kenkyū-buntansha)	山野智基兵庫医科大学, 医学部, 非常勤講師 (00599318) 麸谷博之兵庫医科大学, 医学部, 教授 (30248140) 中込隆之兵庫医科大学, 医学部, 教授 (80434950)
Project Period (FY)	2019-06-28 – 2022-03-31
Keywords	増殖型レトロウイルス / がんウイルス療法 / 骨肉腫 / 肺転移 / 自殺遺伝子療法
Outline of Final Research Achievements	We have developed a retroviral replicating vector (RRV) that specifically infects and multiplies cancer cells and efficiently spreads and propagates within tumors. By loading a suicide gene onto this RRV, tumor cell death can be induced by administration of a drug precursor, which has shown high infection efficiency and excellent therapeutic efficacy in various tumor models. The results of this study demonstrated that the viral therapy has a high antitumor effect in osteosarcoma models. Furthermore, we have demonstrated a proof-of-principle method to efficiently reach and distribute RRV to cancer cells using mesenchymal stem cells as carriers, taking advantage of their ability to accumulate in cancer cells.
Free Research Field	遺伝子細胞治療
Academic Significance and Societal Importance of the Research Achievements	本研究の成果により、骨肉腫肺転移症例へのRRVを用いた自殺遺伝子療法の適応拡大が期待され、臨床応用可能な実用性の高いウイルス療法開発につながることが期待される。骨肉腫のみならず、播種性癌の患者の予後やQuality of Lifeを大きく改善する可能性がある。